Two-Drug combo tested for tough thyroid cancer

NCT ID NCT02143726

Ongoing Disease control Sponsor: Alliance for Clinical Trials in Oncology Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether adding everolimus to sorafenib works better than sorafenib alone for people with advanced Hurthle cell thyroid cancer that no longer responds to radioactive iodine. The study includes 35 participants and measures how long the cancer stays under control. The goal is to see if the combination can shrink tumors or slow growth, though it may also increase side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sorafenib and everolimus
What this could lead to: If successful, this could point toward a more effective drug combination for a rare and hard-to-treat thyroid cancer.
What could go wrong: This is a small, early-phase trial with only 35 participants, so results may not apply broadly. Adding everolimus could also cause more side effects without improving outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

thyroid Hurthle cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

REFRACTORY HURTHLE CELL THYROID CANCER

Contacts and locations

Locations

Fox Chase Cancer Center

Philadelphia, Pennsylvania, 19111, United States
Mayo Clinic

Rochester, Minnesota, 55905, United States
Mayo Clinic in Florida

Jacksonville, Florida, 32224-9980, United States
Memorial Sloan Kettering Basking Ridge

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Bergen

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Memorial Sloan Kettering Commack

Commack, New York, 11725, United States
Memorial Sloan Kettering Monmouth

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau

Uniondale, New York, 11553, United States
Memorial Sloan Kettering Sleepy Hollow

Sleepy Hollow, New York, 10591, United States
Memorial Sloan Kettering Westchester

Harrison, New York, 10604, United States
Mercy Health System

Janesville, Wisconsin, 53547, United States
Nebraska Methodist Hospital

Omaha, Nebraska, 68114, United States
Northwestern University

Chicago, Illinois, 60611, United States
Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210, United States
Siouxland Regional Cancer Center

Sioux City, Iowa, 51101, United States
Southeastern Medical Oncology Center-Clinton

Clinton, North Carolina, 28328, United States
Southeastern Medical Oncology Center-Goldsboro

Goldsboro, North Carolina, 27534, United States
Southeastern Medical Oncology Center-Jacksonville

Jacksonville, North Carolina, 28546, United States
University of Michigan Comprehensive Cancer Center

Ann Arbor, Michigan, 48109, United States
Wayne Memorial Hospital

Goldsboro, North Carolina, 27534, United States